Filing Flows

Filing Flows › Companies › OptimizeRx › Cash flow

OptimizeRx cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$8.6M in Q2 2026 · $18.4M over twelve months

Operating cash flow$8.6M
Capital spending−$35K
Free cash flow+$8.6M
Cash conversion cycle85 days

Analysis

In Q2 2026, OptimizeRx generated $8.6M of operating cash flow and spent $35K on capital projects, leaving free cash flow of $8.6M. That is $4.0M more than in Q2 2025 ($4.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was $18.4M; the largest uses were net borrowing (+) / repaid (−) ($34.6M), capital spending ($77K); besides operations, cash came from other financing ($23.5M), other investing ($217K); the cash balance rose by $7.5M.

Operating cash flow was $8.6M against net income of −$703K. The largest differences: receivables +$7.2M, stock-based pay +$2.2M, accrued liabilities +$1.8M.

Its cash conversion cycle was 85 days (receivables 126 + inventory 0 − payables 41).

Free cash flow

OptimizeRx: free cash flow by quarterOptimizeRx: free cash flow by quarter$1.8MQ3 2024$181KQ4 2024$3.8MQ1 2025$4.6MQ2 2025$3.2MQ3 2025$7.1MQ4 2025−$488KQ1 2026$8.6MQ2 2026
Operating cash flow less capital spending.
OptimizeRx: operating cash flow against capital spendingOptimizeRx: operating cash flow against capital spendingOperating cash flowCapital spending$1.8M$18KQ3 2024$198K$17KQ4 2024$3.9M$27KQ1 2025$4.6M$10KQ2 2025$3.2M$10KQ3 2025$7.1M$11KQ4 2025−$467K$21KQ1 2026$8.6M$35KQ2 2026
Latest (Q2 2026): Operating cash flow $8.6M, Capital spending $35K.

Capital allocation, year by year

OptimizeRx: where the cash came from (up) and went (down), by fiscal yearOptimizeRx: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $726KFY2021: Shares issued $75.5MFY2021: Capital spending −$100K$76.3MFY2021FY2022: Operating cash flow $10.7MFY2022: Shares issued $1.1MFY2022: Capital spending −$81KFY2022: Acquisitions −$2.0MFY2022: Buybacks −$20.0M$11.7MFY2022FY2023: Operating cash flow −$7.2MFY2023: Net borrowing $36.0MFY2023: Asset sales $2.5MFY2023: Capital spending −$87KFY2023: Acquisitions −$82.9MFY2023: Buybacks −$7.5M$38.6MFY2023FY2024: Operating cash flow $4.9MFY2024: Net borrowing −$4.0MFY2024: Capital spending −$112K$4.9MFY2024FY2025: Operating cash flow $18.7MFY2025: Net borrowing −$8.0MFY2025: Shares issued $352KFY2025: Capital spending −$58K$19.1MFY2025
Over these 5 years operating cash flow totalled $27.7M; the largest uses were acquisitions ($84.9M) and buybacks ($27.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$24.1M
Debt$19.7M
Net cash$4.4M
Due within a year$2.0M

OptimizeRx funds itself: free cash flow was $18.4M over the last twelve months, and $24.1M of cash and investments stands against $19.7M of debt ($2.0M due within a year, 12.0× covered by cash).

OptimizeRx: debt maturities by year (FY2024)OptimizeRx: debt maturities by year (FY2024)$2.0MYear 1$2.0MYear 2$30.3MYear 3
Principal due in each year as disclosed in the annual report, against $24.1M of cash and investments now.

Where the cash came from and went

OptimizeRx: sources (+) and uses (−) of cash, Q2 2026OptimizeRx: sources (+) and uses (−) of cash, Q2 2026Net borrowing (+) / repaid (−)−$28.9MOther financing$24.3MOperating cash flow$8.6MCash drawn (+) / kept (−)−$3.9MTaxes on employees’ shares−$46KCapital spending−$35KNot reconciled$11K
OptimizeRx: sources (+) and uses (−) of cash, TTM to Q2 2026OptimizeRx: sources (+) and uses (−) of cash, TTM to Q2 2026Net borrowing (+) / repaid (−)−$34.6MOther financing$23.5MOperating cash flow$18.4MCash drawn (+) / kept (−)−$7.5MOther investing$217KCapital spending−$77KNot reconciled$11K

From profit to cash

OptimizeRx: net income to operating cash flow, Q2 2026OptimizeRx: net income to operating cash flow, Q2 2026Net income−$703KDepreciation & amortization$1.1MStock-based pay$2.2MReceivables$7.2MPayables−$1.7MAccrued liabilities$1.8MDeferred revenue$40KPrepaid and other assets$209KIncome taxes payable−$1.5MOperating cash flow$8.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026126—4185
Q1 2026158—43115
Q4 2025100—2179
Q3 2025116—2294
Q2 2025103—2380
Q1 2025146—29117
Q4 202492—2270
Q3 2024110—3476

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$8.6M−$35K−$28.9M—−$3.9M$8.6M
Q1 2026−$467K−$21K−$2.7M—$3.2M−$488K
Q4 2025$7.1M−$11K−$2.5M$14K−$3.8M$7.1M
Q3 2025$3.2M−$10K−$500K—−$2.9M$3.2M
Q2 2025$4.6M−$10K−$4.5M—−$12K$4.6M
Q1 2025$3.9M−$27K−$500K—−$3.2M$3.8M
Q4 2024$198K−$17K−$2.5M—$2.7M$181K
Q3 2024$1.8M−$18K−$500K—−$1.2M$1.8M

OptimizeRx: income statement and cash flow

OptimizeRx, Q2 2026: revenue $20.5M (-30% year over year), operating margin -0.4%. The chart follows the revenue to costs, profit and cash.

OptimizeRx: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.